Title and Organization:
Ellen Goldberg, MS, MBA, is founder and president of CHORD Consulting Services, a firm that provides product strategy and marketing consulting to companies driving step-change improvements in health care, and director, Castle Biosciences. Ellen has focused her career on developing and commercializing ground-breaking technologies in life-threatening and life-altering diseases. As VP of marketing at Crescendo Bioscience (now a wholly-owned subsidiary of Myriad Genetics, Inc.), she launched Vectra™ DA, a multi-biomarker blood test that enhances disease assessment and enables treatment changes to reduce progression in rheumatoid arthritis. Prior to Crescendo, Ellen held many roles at Genomic Health, Inc., where she launched the Oncotype DX® Breast Cancer Assay, a standard of care test that empowers over 80,000 women annually to make better decisions about chemotherapy. While there, in addition to leading the marketing team, she started the market strategy group, working on pipeline products—all of which have now been commercialized—for people diagnosed with DCIS (ductal carcinoma in situ), colon cancer, and prostate cancer. Ellen began her career as a strategy consultant with Booz Allen Hamilton, working for companies focused on companion diagnostics, medical devices, and pharmaceuticals; she then initiated and guided development of new drug delivery combinations at ALZA Corporation as part of the new product planning team. She earned her bachelor’s degree in chemistry from Yale University, where she graduated cum laude and Phi Beta Kappa, her master’s degree in chemistry from Stanford University, and her MBA from the Stanford University Graduate School of Business. Ellen is a Fellow of the fourth class of the Health Innovators Fellowship and a member of the Aspen Global Leadership Network.